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To the editor: 
Breathomics in asthma is a rapidly growing area of significant scientific interest, as 
indicated by a recently published review, two research articles, and their accompanying 
editorials in high impact pneumology journals [1–5]. The repeatedly observed associations 
between breath volatile organic compounds (VOCs) and sputum or blood inflammatory cells 
[2,3] suggest that breathomics are on the brink of introduction as a valuable clinically tool. 
However, there are also major concerns about unresolved methodological issues and a 
general paucity of high-quality data [1,6]. In this letter we detail our concerns with breath-
omics based on data from a cohort of adult asthma patients with a broad spectrum of clinical 
phenotypes.   
 
In the adult arm of the ALLIANCE asthma cohort we prospectively recruited patients 
with an established diagnosis of asthma [7] across different severity grades and 
inflammatory phenotypes as identified by FeNO, blood and sputum differential cell counts 
[8]. As recently recommended [5], the patients were clinically well characterized, the asthma 
diagnosis was thoroughly established, and breath VOCs were compared between different 
asthma phenotypes.  
For the analysis we included 133 adult patients that attended their 12-month follow-
up visit from 2015 to 2016 at LungenClinic Grosshansdorf. To examine patients under stable 
conditions, all visits were scheduled at least four weeks after an acute severe exacerbation 
(defined as oral steroid burst therapy for at least three consecutive days) or asthma-related 
hospitalization. The study (NCT02419274) was approved (Medical School Luebeck ethics 
committee, Az.12-215) and all participants gave their written informed consent before 
inclusion. 
The patients were grouped into five clinically established phenotypes according to 
disease severity (2014 ERS/ATS guidelines [9]), type 2 airway inflammation (blood 
eosinophils ≥300/µl), and smoking status (Panel-figure 1.A). We performed spirometry, 
body-plethysmography, impulse-oscillometry, and measured FeNO [8]. Blood differential cell 
counts and induced sputum [10] were assessed by established protocols. The collection and 
analysis of breath VOCs is described in detail in [11]. Patients inhaled active-carbon filtered 
room air and exhaled into an aluminum reservoir tube to avoid the use of sampling bags. 
During 5min collection, 2.5L breath were loaded onto each of two Tenax®TA adsorption 
tubes, which were analyzed by gas-chromatography/mass-spectrometry (GC/MS). 134 VOCs 
were assessed in total (listed in Table 2 of [11]). Fourty VOCs were excluded because in at 
least in 85% of the study participants the values were below the limit of detection. VOC data 
was log-transformed prior to analysis.  
 
The validity and plausibility of the VOC data is supported by several aspects and 
observations. (I) The method used for collection and analysis was benchmarked in the 
Peppermint oil trial [12,13], in which we demonstrated washout kinetics of peppermint oil 
compounds after ingestion of a respective capsule. (II) The two simultaneously collected 
adsorption tubes in this study showed a very close agreement (median r>0.87). (III) As 
expected, acetone and isoprene were the most abundant VOCs in breath, while cleaning and 
disinfectant related VOCs like propanol-1, propanol-2 and ethanol were predominantly 
found in room air. (IV) We found highly significant differences for smoking related VOCs like 
acetonitrile, benzene and cyclohexadien (p<0.001, respectively) between active smokers and 
non-smokers (Panel-figure 1.A). In addition, these compounds indicated that five patients 
potentially misjudged their smoking behavior or experienced a substantial passive smoke 
exposure. (V) In line with others [14], we found higher levels of isoprene in male subjects 
(p<0.001).  
Patients’ characteristics according to asthma phenotypes are shown in panel-figure 
1.A. In contrast to others, we observed no statistically significant correlations between 
breath VOC levels and markers of inflammation like sputum eosinophils, blood eosinophils, 
sputum neutrophils or exhaled NO, after adjusting the p-values for multiple testing using the 
Benjamini-Hochberg method [15]. The histograms of all unadjusted p-values of the 
correlations between VOCs and markers of inflammation are shown in panel-figure 1.G.  We 
tested these correlations also within the subgroups of patients with comparable results. 
Panel-figures 1.C-F show the correlations between sputum neutrophils and eosinophils for 
three markers suggested to discriminate between eosinophilc or neutrophilic asthma [3]. 
There were also no significant differences in breath VOCs between four different sputum 
inflammatory phenotypes (eosinophil cut-off 3% and neutrophil cut-off of 61% [16]). In a 
univariate analysis we found 9 VOCs with differences between severe and mild asthmatics 
and only one VOC with a difference between high and normal blood eosinophils. After 
adjusting for multiple testing all respective p-values were > 0.11. Interestingly, the largest 
difference between moderate and severe asthmatics was found for an unidentified VOC 
(unadjusted p<0.001) that was suspected to be COPD related in a previous study [11].  
 A recent paper [3] suggests propanol-1 as a potential marker to discriminate between 
inflammatory phenotypes. Although propanol-1 is known to occur in humans and associated 
with some diseases and metabolic disorders, propanol-1 is a major part of hand and surface 
disinfectant and detected in high concentrations in room air of hospital environments. We 
found no difference of propanol-1 between groups or sputum inflammatory phenotypes [16] 
in our study (Panel-figure 1.C). The spectrum of compounds associated with asthma is very 
broad and diverse between studies. A certain overlap between studies appears to exist for 
alkanes in general, but not for individual alkanes. These as well as other markers or 
combination of markers suggested to be associated with asthma (reviewed in [1]) were 
either not among the VOCs that we detected [11] or showed no significant differences 
between groups. In an effort to find clinically relevant breath VOCs we used a 
comprehensively characterized asthma cohort and used a breath analysis method that has 
been benchmarked against others [13], but we were not able to reproduce the positive 
results of other asthma breath VOC trials.  
There is an increasing interest in breath biomarkers [5] but it is important to keep in 
mind that still no validated VOC biomarker or biomarker pattern exists for any disease 
(Breath Summit 2019, Loughborough). Despite STARD guidelines, external validation is still 
rare in breath VOC studies [1] and importantly it is also heterogeneously defined. To 
evaluate the clinical value of a novel test system the discrimination model from the training 
patient cohort should be tested in independent patients. Showing that two discrimination 
models, derived from independent patient groups, result in a similar list of markers [3] or 
lead to similar clustering of data [2] is a major improvement with respect to independent 
data validation. However, a true external validation still is missing. The reason for the 
currently limited success in this field maybe remaining methodological issues or the fact that 
readily detectable asthma VOC biomarkers do not exist. Despite our high quality standards 
we can also not exclude that methodological or sensitivity issues are responsible for the non-
supportive findings presented here. However, breath biomarkers are not ready for clinical 
use until all standards are met.  
Many valuable insights were gained from the numerous breath VOC studies, especially 
increasing our awareness for interfering environmental, lifestyle and metabolic factors and 
for the need of a more standardized methodological approach. Considering these interfering 
factors it currently appears crucial to identify breath VOCs to be able to assess their origin 
and biochemical meaning. Databases like PubChem, mVOC or HMDB provide detailed 
information for VOCs on endogenous production in different species, the relationship to 
human diseases as well as the occurrence in foods or products potentially playing a role for 
exogenous exposures. Available standardized collection methods (e.g. ReCIVA breath 
sampler, Owlstone, UK) and efforts to make collection and analysis methods more 
comparable between research groups (Peppermint oil consortium) will strengthen research 
activities that involve multiple centers [3,11] and thereby increase patient numbers and the 
statistical power – which is desperately needed for a truly external validation.  
Yet, at this point, we would like to add a word of caution to the ongoing discussion, as 
we did not find any significant correlations between VOCs and inflammatory markers in a 
well-characterized cohort of adult patients with asthma with a broad spectrum of clinical 
phenotypes. 
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Multi-Panel Figure 1: A: patient demographics according to asthma phenotypes. Data are presented as median 
(IQR). Statistics: Kruskal-Wallis-Anova. Abbreviations: BMI, body mass index; PY, Pack-Years; ACT, Asthma 
Control Test; ICS, inhaled corticosteroids; OCS, oral corticosteroids; % pred., % of predicted; FEV1, forced 
expiratory volume in 1 sec; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; sRtot, 
specific total airway resistance; R5Hz, resistance at 5Hz; FDRabs, frequency dependence of resistance 
(resistance at 5Hz – resistance at 20 Hz). & missing values, # Omalizumab or Mepolizomap. B: GC/MS 
chromatogram of one representative patient with inserts and arrows indicating the retention time (RT) for 
propanol-1, hexane, 2-hexanone and nonanal [3]. The black lines indicates the total ion content (TIC), the insert 
colored plots show specific masses of the respective VOCs. C-E: correlation between VOCs and sputum 
neutrophils (%). All patients and subgroup correlations not significant (unadjusted p-value >0.05). F: correlation 
between hexane and sputum eosinophils (%). All patients and subgroup correlations not significant (unadjusted 
p-value >0.05), except for smokers (r = -0.45, unadjusted p value = 0.02, adjusted p value=0.48). Selection of 
VOCS based on published data by [3]. As shown in B, 2-hexanone was not detectable in our samples. G: 
histograms of unadjusted p-values for the correlation between all detected VOCs and sputum neutrophils and 
eosinophils (%), exhaled NO (FeNO), and blood eosinophils (%). a.u. = arbitrary units 
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